Physician profile
Biju Abraham
NPI 1104059427
$1,758.34
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $432 · 2020: $638 · 2021: $672 · 2022: $16.59.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $884.04 | 2019-2022 | |
| Redhill Biopharma INC. | $306.72 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $142.55 | 2020-2021 | |
| Ferring Pharmaceuticals INC. | $59.15 | 2019-2021 | |
| Gilead Sciences, INC. | $51.50 | 2019-2021 | |
| Braintree Laboratories, INC. | $40.75 | 2019 | |
| Celgene Corporation | $38.92 | 2021 | |
| Janssen Biotech, INC. | $35.90 | 2019-2021 | |
| Alfasigma USA, INC. | $35.80 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.83 | 2020-2021 | |
| Intercept Pharmaceuticals, INC. | $24.25 | 2020 | |
| Allergan, INC. | $22.72 | 2019 | |
| Glaxosmithkline, LLC. | $20.46 | 2020 | |
| Bausch Health US, LLC | $19.28 | 2020 | |
| Ironwood Pharmaceuticals, INC | $18.70 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $17.46 | 2019 | |
| Genentech USA, INC. | $11.31 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Biju Abraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.